ART Modulation of Viral Pathogenesis

$1,579,497R01FY2025DENIH

Univ Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications, trials & patents

Paper 39648698 Paper 39361305 Paper 39140770 Paper 37330471 Paper 37272197 Paper 36786605 Paper 36761994 Paper 35247913 Paper 35234354 Paper 35089062 Paper 34523970 Paper 34515687 Paper 33677480 Paper 33411764 Paper 32407363 Paper 32161170 Paper 32158775 Paper 32153113 Paper 31629226 Paper 31624104 Paper 30716130 Paper 30533204 Paper 30455728 Paper 30429324 Paper 30271878 Paper 30212584 Paper 30021906 Paper 30021895 Paper 29970461 Paper 28723706 Paper 28662221 Paper 28649136 Paper 28611469 Paper 28459883 Paper 28324233 Paper 28104650 Paper 27928018 Paper 27584730 Paper 27307567 Paper 27109286 Paper 27109281 Paper 26476352 Paper 26327622 Paper 26301593 Paper 26242311 Paper 26148192 Paper 25591541 Paper 25341731 Paper 25127040 Paper 25064127 Paper 24681415 Paper 24623417 Paper 24227849 Paper 23986576 Paper 23874201 Paper 23449792 Paper 23428639 Paper 22925337 Paper 22752304 Paper 22278234 Paper 22142220 Paper 22045987 Paper 21819957 Paper 21792887 Paper 21685375 Paper 21178961 Paper 21169470 Paper 21141701 Paper 20980519 Paper 20703254 Paper 20696959 Paper 20646303 Paper 20637239 Paper 20299510 Paper 19911999 Paper 19759127 Paper 19726500 Paper 19564611 Paper 19381272 Paper 19381257 Paper 19252139 Paper 19019773 Paper 18688856 Paper 18367536 Paper 18316607 Paper 18234764 Paper 18079361 Paper 18019828 Paper 17762574 Paper 17762570 Paper 17699731 Paper 17672039 Paper 17349582 Paper 17121789 Paper 17082322 Paper 17066452 Paper 16641275

Abstract

ABSTRACT This is the renewal application of 5R01DE018304-15. It responds to NOT-DE-25-038 / "Basic and Translational Oral Health Research Related to HIV/AIDS." Kaposi Sarcoma (KS) is the most common cancer in people living with HIV today, whether in the US or in Sub-Saharan Africa, where the majority of PLWH reside. KS can form in the oral cavity. Oral KS is considered a marker-aggressive disease. KS can occur in severe immune- compromised people but also in PLWH, in whom ART suppresses HIV replication to below 50 copies/ml. Kaposi sarcoma herpesvirus (KSHV) is entrenched in populations for increased risk of HIV acquisition, including members of racial and socioeconomic minorities. Not much is known about the effect of ART on Kaposi sarcoma- associated herpesvirus (KSHV) oral transmission, oral and systemic KS disease, or the latent KSHV reservoir. We propose to investigate the impact of ART in the context of chemotherapy for KS and define novel disease biomarkers. We apply advanced technologies and analytics to one of today's largest clinical trial collections to allocate HIV+ KS patients to the best therapy for them.

View original record on NIH RePORTER →